Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07646587 · ClinicalTrials.gov registry record · Phase 2
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
A Phase 2 study, sponsored by Windward Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT07646587 is a Phase 2 study that is actively recruiting participants, run by Windward Bio. The registered enrollment target is 105 participants.
The verdict
NCT07646587, a Phase 2 study, is actively recruiting participants, sponsored by Windward Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
Interventions
- DRUG Placebo
- DRUG WIN378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2028-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07646587
The ClinicalTrials.gov registry entry for NCT07646587 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windward Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07646587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07646587 about?
NCT07646587 is a clinical study titled "A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)". This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and sympto...
What is the current status of trial NCT07646587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2026-06-02. Estimated completion is 2028-01-07.
What interventions are being tested in trial NCT07646587?
The interventions under investigation include: Placebo (DRUG), WIN378 (DRUG).
Who is sponsoring clinical trial NCT07646587?
This trial is sponsored by Windward Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.